At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 36 enrolled
Drug / intervention
DCR-AUD +1 moredrug
Likely dose
DCR-AUD 160 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Double-blind, Placebo-controlled, Single-ascending Dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of DCR-AUD in Healthy Volunteers
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company·interventional·Posted Aug 25, 2021·Updated Dec 27, 2024
In Brief
A Phase 1 clinical trial evaluating DCR-AUD and Placebo for DCR-AUD for Alcohol Use Disorder (AUD). Completed, enrolled 36 participants across 1 site.
Detailed Summary
DCR-AUD will be evaluated for safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcohol Use Disorder (AUD)
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedAug 2021
Enrollment StartSep 2021
Primary CompletionDec 2022
TodayJul 2026
First PostedAug 25, 2021
Enrollment StartSep 21, 2021
Primary CompletionDec 31, 2022
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 4.9 years ago
Interventions
DCR-AUDdrug
DCR-A1203, the drug substance of DCR-AUD, is a synthetic double-stranded (hybridized duplex) RNA oligonucleotide conjugated to GalNAc ligands that enable specific hepatic access and uptake after subcutaneous administration. DCR-AUD is a sterile solution of DCR-A1203 at a concentration of 160 mg/mL in water for injection (WFI).
Placebo for DCR-AUDdrug
0.9% saline for injection